RESUMO
Fifty-three inoperable lung cancer patients were treated with radiotherapy combined with immunostimulation with BCG. A good response was obtained in 30 patients (56%); the results were not significantly different than those obtained with a control group of 50 lung cancer patients matched by age, sex and stage of the disease (24 out of 50 equals 46%). These short-term results were compared with the immunologic "status" of patients evaluated before treatment by the parameters monitoring in vivo and in vitro delayed type hypersensitivity. The good response to therapy was documented in a higher percentage of patients with positive skin tests to recall and standard antigens and with normal values of lymphocyte transformation with PHA and Rosette E-forming cells, in comparison with patients with low levels of immunocompetence. An impairment of the cell-mediated immune response was found after combined therapy, presumably due to radiotherapy. BCG was not able to restore the patient's immunocompetence, no effect on host's immune reactivity was demonstrated. As regards humoral immunity, the patients with low levels of IgG before treatment (12/14) showed a good response.
Assuntos
Imunoterapia/métodos , Neoplasias Pulmonares/terapia , Animais , Formação de Anticorpos , Vacina BCG/uso terapêutico , Testes Imunológicos de Citotoxicidade , Humanos , Hipersensibilidade Tardia/imunologia , Reação de Imunoaderência , Imunidade Celular , Imunoglobulinas/isolamento & purificação , Neoplasias Pulmonares/imunologia , Neoplasias Pulmonares/radioterapia , MasculinoAssuntos
Neoplasias da Mama/tratamento farmacológico , Cloranfenicol/administração & dosagem , Metotrexato/administração & dosagem , Metástase Neoplásica , Administração Oral , Neoplasias Ósseas/tratamento farmacológico , Combinação de Medicamentos , Feminino , Humanos , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Cutâneas/tratamento farmacológicoRESUMO
49 patients with advanced lung cancer underwent a combined treatment including radiochemoimmunotherapy. Before and at the end of the combined treatment, the immune status of the patients has been evaluated by testing the immunoreactivity to PPD in vivo and the phytohemagglutinin lymphocyte response and the rosette-forming cells in vitro. While the in vitro tests were not significantly modified by immunostimulation, as regards the immunoreactivity to PPD, we observed a positive conversion at the end of the treatment in 11 out of 25 patients who showed a negative reaction before therapy. All the patients who converted from negative to positive showed also a good response to therapy with regression or no progression of the tumor. Survival curves confirmed the prognostic value of PPD reactivity.